Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Bailisi Kang Biomedicine (Hangzhou)

Request full access

Oncology biotherapeutics and tumor-targeting antibody-drug conjugates (ADCs)

Hangzhou, ChinaFounded 2017

About Bailisi Kang Biomedicine (Hangzhou)

Bailisi Kang Biomedicine, also known as Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (BlissBio), is a clinical-stage biopharmaceutical company founded in December 2017 by pharmaceutical veterans Dr. Ziping Wei and Yu Hong Zhou in Hangzhou, China. The company focuses on the discovery, development, and commercialization of anti-tumor biotherapeutics, with a specialization in antibody-drug conjugates (ADCs). The core team has experience in developing various biotherapeutics, including monoclonal antibodies, bispecific antibodies, and ADCs, with nine products they contributed to receiving market approval.

BlissBio's business model centers on its proprietary and patented ADC technology platform, developing a pipeline of oncology drugs to address unmet medical needs. The company has its own GMP-certified manufacturing facility capable of producing antibodies and ADCs for clinical trials and early-stage commercialization. Its revenue model involves strategic collaborations, licensing agreements, and milestone payments. A key partnership is with the Japanese pharmaceutical firm Eisai Co., Ltd. In May 2023, the two companies entered into a joint development and strategic collaboration agreement for BlissBio's leading product, BB-1701. The agreement includes upfront payments, milestone payments that could total up to $2 billion, and royalties on sales. Eisai gained global development and commercialization rights for BB-1701, excluding Greater China.

The company's main product candidate, BB-1701, is an ADC that targets the HER2 protein, which is expressed in various solid tumors like breast and lung cancer. It combines an anti-HER2 antibody with Eisai's anticancer agent, eribulin, as the payload. BB-1701 is currently in Phase I/II international clinical trials in the U.S. and China. The company's pipeline also includes other ADC candidates like BB-1705, which targets EGFR for solid tumors, and BB-1712, targeting B7-H3, both of which are in clinical development. BlissBio has successfully raised capital to fund its research and development, including a Series B round of $61.3M in April 2021 and a Series B++ financing from Eisai in June 2023.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
14.3/100
Links
Website

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Jun 2023 — — Eisai ↗
SERIES B✓Equity / VC Jan 2023 $14M $55M Sherpa Venture Partners · In Capital · Oriental Fortune Capital ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Bailisi Kang Biomedicine (Hangzhou) website traffic

Latest recorded traffic for Bailisi Kang Biomedicine (Hangzhou) is 90 monthly website visits, down 67.9% over the last three months.

Latest monthly visits90 3-month web change-67.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Bailisi Kang Biomedicine (Hangzhou) in the Hangzhou ecosystem

Live from Dealroom

The Bailisi Kang Biomedicine (Hangzhou) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • VMS Group
  • In Capital
  • Sherpa Venture Partners
  • Oriental Fortune Capital
  • Eisai
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Hangzhou HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Bailisi Kang Biomedicine (Hangzhou) on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Bailisi Kang Biomedicine (Hangzhou)’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.